paediatrics Brussels 17

Moxon-Emre et al

Table 1. Patient Characteristics, Medical Variables, and Assessment Details

Standard- Dose CSR PF Boost (n 51)

Reduced- Dose CSR PF Boost (n 28)

Standard-Dose CSR TB Boost (n 9)

Reduced-Dose CSR TB Boost (n 23)

Total (N 113)

Characteristic

No.

% No.

% No.

% No.

% No.

%

P

CSR

111 98.2

Chemotherapy†

102 90.3 41 80.4 9

100.0 27 96.4 23

100.0

.017

Protocol A

3

2

1 1

B C D E

21 24 17 30

20

4

20

14

1 8

2

1

21

F

2 4 1

2 1

G H

2

Deceased

22 19.5 12 23.5 3 83 73.5 30 58.8 7 67 59.3 17 33.3 4

33.3

6 21.4 1

4.3

.17 .12

Gross total resection‡ Clinical risk (average risk)

77.8 24 85.7 20 44.4 23 82.1 22

87.0 95.7

.001

Hydrocephalus

Presence at diagnosis Requiring CSF diversion Third ventriculostomy

90 79.6 39 76.5 5 54 47.8 18 35.0 5

55.6 25 89.3 19 55.6 14 50.0 15

82.6 65.2 13.0 34.8 14.4 13.0 26.1 21.7

.16 .10 .32 .78 .79 .26 .71 .49 .47

6

5.3

2 2

3.9 0 3.9 3

0.0

1

3.6 3

EVD only

18 15.9

33.3 22.2 22.2 22.2 22.2

5 17.9 8 8 28.6 4 3 10.7 3 9 32.1 6 3 10.7 5

.004

VPS

30 26.5 14 27.5 2

1 revision

17 15.0 25 22.1 18 15.9

9 17.6 2 7 13.7 2 8 15.7 2

Mutism§

Motor deficits

Cranial nerve deficits¶

2 9

1.8 8.0

2 5

3.9 0 9.8 1

0.0

0 2

0.0 0 7.1 0

0.0 0.0

Meningitis Male sex

11.1

79 69.9 39 76.5 8

88.9 19 67.9 11

47.8

.049

Age at diagnosis, years

.29

Mean

7.51 3.37

7.89 3.69

8.44 3.69

6.54 3.32

7.48 3.47

SD

Range

1.09-14.95

1.92-14.54

3.53-14.48

1.69-13.64

1.09-14.95

Time from diagnosis to first assessment, years#

.13

Mean

1.21 1.68

1.61 2.16

0.82 0.93

0.93 1.14

0.77 0.95

SD

Range

0.05-8.73

0.05-8.73

0.08-2.48

0.10-5.33

0.05-4.11

Time from diagnosis to last assessment, years

.001

Mean

6.06 3.42

7.28 3.49

3.2

6.8

3.26

SD

1.17

3.42

1.51

Range

1.47-14.16

1.63-14.16

2.05-5.17

2.25-12.39

1.47-5.63

No. of assessments

.34

Average

3

3

2

3

2

Range

1-7

1-7

1-6

1-7

1-6

Patients seen for a single assessment .60 NOTE. Test versions used to assess intellectual functioning included: Wechsler Intelligence Scale for Children (eds 3 and 4), Wechsler Preschool and Primary Scale of Intelligence (revised and ed 2), Wechsler Abbreviated Scale of Intelligence, and Wechsler Adult Intelligence Scale (eds 3 and 4). Abbreviations: CSF, cerebrospinal fluid; CSR, craniospinal irradiation; EVD, external ventricular drain; PF, posterior fossa; SD, standard deviation; TB, tumor bed; VPS, ventriculoperitoneal shunt. P values reflect 2 analyses conducted between four radiation treatment groups. †Chemotherapy protocols and associated agents are as follows: A, Baby POG (cyclophosphamide, vincristine, cisplatin, and etoposide); B, ICE (ifosfamide, carboplatin, and toposide); C, CCG 9961 (vincristine, lomustine/cyclophosphamide, and cisplatin); D, POG 9631 (etoposide, cisplatin, cyclophosphamide, and vincristine); E, SJMB 03 (vincristine, cisplatin, and cyclophosphamide); F, ACNS 0331 (vincristine, cisplatin, lomustine, and cyclophosphamide); G, 99703 (cisplatin, vincristine, cyclophosphamide, and etoposide); and H, MOPP (mechloroethamine, vincristine, procarbazine, and prednisone). Patients who did not receive chemotherapy were treated before 1999. ‡Data unavailable for one patient. §Patients classified as having mutism if they had diminished speech output, linguistic difficulties, or dysarthria after surgery. Patients classified as having motor deficits if they had ataxia, dysmetria, or hemiparesis on neurologic examination. ¶Patients classified as having cranial nerve deficits if they had any cranial nerve palsy on neurologic examination (eg, seventh nerve palsy as diagnosed by facial weakness). #Seventy-six patients assessed within 12 months from diagnosis. 32 28.3 17 33.3 4 44.4 3 10.7 8 34.8

1762

J OURNAL OF C LINICAL O NCOLOGY

© 2014 by American Society of Clinical Oncology

2015 from 139.18.235.208 Information downloaded from jco.ascopubs.org and provided by at UNIVERSITAETSKLINIKUM LEIPZIG on February 17, Copyright © 2014 American Society of Clinical Oncology. All rights reserved.